Qiangfei Xia to Treatment Outcome
This is a "connection" page, showing publications Qiangfei Xia has written about Treatment Outcome.
Connection Strength
0.295
-
Feng MX, Zhang JX, Wan P, Qiu BJ, Gu LH, Zhang JJ, Xia Q. Hepatic artery reconstruction in pediatric liver transplantation: Experience from a single group. Hepatobiliary Pancreat Dis Int. 2020 Aug; 19(4):307-310.
Score: 0.076
-
Wan P, Xu D, Zhang J, Li Q, Zhang M, Chen X, Luo Y, Shen C, Han L, Xia Q. Liver transplantation for biliary atresia: A nationwide investigation from 1996 to 2013 in mainland China. Pediatr Transplant. 2016 Dec; 20(8):1051-1059.
Score: 0.058
-
Wan P, Zhang J, Long X, Li Q, Xu N, Zhang M, Chen X, Han L, Xia Q. Serum levels of preoperative a-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. Eur J Gastroenterol Hepatol. 2014 May; 26(5):553-61.
Score: 0.050
-
Wan P, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ, Xia Q. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison. World J Gastroenterol. 2014 Apr 21; 20(15):4393-400.
Score: 0.050
-
Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study. Hepatobiliary Pancreat Dis Int. 2022 Apr; 21(2):106-112.
Score: 0.021
-
Ye SL, Yang J, Bie P, Zhang S, Chen X, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Lv Z. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer. 2018 03 02; 18(1):247.
Score: 0.016
-
Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2016 Feb 09; 7(6):6639-48.
Score: 0.014
-
Cui J, Li Z, Qian LB, Gao Q, Wang J, Xue M, Lou XE, Bruce IC, Xia Q, Wang HP. Reducing the oxidative stress mediates the cardioprotection of bicyclol against ischemia-reperfusion injury in rats. J Zhejiang Univ Sci B. 2013 Jun; 14(6):487-95.
Score: 0.012